SB-121
Phase 1Small molecule
SB-121 is one of 55 small molecule programs targeting Tic Disorder. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
71 competitors in Tic Disorder
#DrugCompanyPhaseTrials
1Zyprexa
MMODAG GmbH
Approved
Intuniv
PPromius Pharma, LLC
Approved
Buspar
Bristol-Myers SquibbPhase 3
Abilify
OtsukaPhase 3
Vitrakvi
BayerPhase 2
Lynparza
AstraZenecaPhase 2
Ibrance
PfizerPhase 2
Retevmo
Eli LillyPhase 2
Balversa
Johnson & JohnsonPhase 2
Haldol
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SB-121. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SScioto Biosciences, Inc.